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Abstract
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the 
understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, 
is a murine–human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A sec-
ond generation of anti-CD20 mAbs has been designed to be more effective, better tolerated, and of lower immunogenicity. 
These include the humanized versions: ocrelizumab, obinutuzumab, and veltuzumab, and the fully human, ofatumumab. We 
conducted a literature search of relevant randomized clinical trials in the PubMed database and ongoing trials in Clinicaltri-
als.gov. Most of these trials have evaluated intravenous ocrelizumab or subcutaneous ofatumumab in rheumatoid arthritis, 
multiple sclerosis, or systemic lupus erythematosus. Understanding how newer anti-CD20 mAbs compare with rituximab 
in terms of efficacy, safety, convenience, and cost is important for guiding future management of anti-CD20 mAb therapy 
in autoimmune diseases.
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Introduction
Anti-CD20 monoclonal antibodies (mAbs) are used to 
achieve B cell depletion, and were initially developed to 
treat B cell proliferative disorders, including non-Hodgkin’s 
lymphoma (NHL) and chronic lymphocytic leukemia (CLL). 
Anti-CD20 mAbs have subsequently been tested and used 
in the treatment of the autoimmune disorder rheumatoid 
arthritis (RA) based on the rationale that the removal of the 
autoantibody producing or T cell-activating B cells would 
lead to clinical improvement [1]. The clear clinical benefits 
of anti-CD20 mAb treatment in RA, particularly in patients 
refractory to other available treatments, has led to the expan-
sion of anti-CD20 mAbs for other autoimmune diseases with 
both T cell and B cell etiology, including systemic lupus 
erythematosus (SLE) and multiple sclerosis (MS).
CD20 is a transmembrane calcium channel implicated 
in B cell activation, proliferation, and differentiation [2]. 
It is present on the surface of B cells in the late pre-B cell 
through mature memory B cell stages. Therefore, anti-CD20 
mAbs target B cells in this intermediate stage of develop-
ment, sparing early pre-B cells and plasma cells, thus allow-
ing for retention of long-term immune memory and B cell 
reconstitution following depletion. Due to the maintenance 
of antibody production by plasma cells, administration of 
anti-CD20 mAbs almost completely depletes peripheral B 
cells, but antibody levels are not dramatically reduced [3]. 
This suggests that the clinical benefits of this type of B cell 
depletion therapy may stem from the loss of other prominent 
B cells functions such as antigen presentation, production of 
inflammatory cytokines, activation of T cells, and creation 
of ectopic lymphoid follicles [4].
Rituximab, a murine–human chimeric anti-CD20 mAb, 
was the first anti-CD20 mAb developed as a therapeutic 
agent. It was introduced in 1997 and has since gained FDA 
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approval for the treatment of NHL, CLL, RA, granulomato-
sis with polyangiitis (GPA), and microscopic polyangiitis. 
It was also found in some studies to be effective in other 
autoimmune conditions including SLE, relapsing-remitting 
MS (RRMS), and pemphigus [5–7]. Unfortunately, human 
anti-chimeric antibodies (HACA) against rituximab often 
develop with treatment due to rituximab’s chimeric makeup. 
Clinically, immunogenicity of rituximab is suspected to play 
a detrimental role in efficacy and tolerability.
New generations of anti-CD20 mAbs that are either 
humanized or fully human have been developed in recent 
years to address the issue of immunogenicity. However, their 
use could lead patients to develop human anti-human anti-
bodies (HAHA) instead. The humanized versions include 
ocrelizumab, veltuzumab, and obinutuzumab, while ofa-
tumumab is currently the only available fully human anti-
CD20 mAb (see Table 1). To boost efficacy, many of the 
second-generation anti-CD20 mAbs have increased binding 
affinity to the Fc receptor on B cells and increased com-
plement-dependent cytotoxicity (CDC) and/or antibody-
dependent cellular cytotoxicity (ADCC) [8]. Their expected 
superiority over rituximab was one of the driving forces for 
their development in recent years, but another contributing 
factor was likely rituximab’s patent expiration in September 
2016 in the United States.
Numerous clinical trials of these agents in various auto-
immune conditions have been completed, and more are 
underway. Ongoing studies of the long-term safety profile 
will be needed to determine the risk of infections, malig-
nancy, and other serious adverse effects. Obinutuzumab and 
ofatumumab have been FDA approved for CLL, but their use 
in autoimmune disorders is still being investigated. Ocreli-
zumab has recently been approved for RRMS, and repre-
sents the first approved treatment for primary progressive 
MS (PPMS). Therefore, it appears that the new generation 
of anti-CD20 mAbs will have important roles in the future 
of treatment for MS, and likely other autoimmune diseases 
as well. To provide a better understanding of the latest 
advances in the use of next-generation anti-CD20 mAbs for 
autoimmune diseases, including potential advantages and 
drawbacks, we have conducted a review of both completed 
and ongoing clinical trials for RA, MS, SLE, and pemphigus 
(see Table 2).
Anti‑CD20 mAbs in rheumatoid arthritis
RA is a common autoimmune, inflammatory disease of the 
joints that affects up to 1% of the US population. Rituximab 
is FDA approved for use with methotrexate (MTX) in RA 
patients who have had inadequate results with a tumor necro-
sis factor (TNF) antagonist. The development of next-gen-
eration anti-CD20 mAbs for use in autoimmune disease had 
initially focused on RA due to its relatively high prevalence.
Ocrelizumab in RA
The use of intravenous (IV) ocrelizumab for the treatment 
of RA was studied in four phase III, international, rand-
omized, double-blind, placebo-controlled trials: SCRIPT, 
STAGE, FILM, and FEATURE. STAGE [9], FILM [10], 
and FEATURE [11] studied ocrelizumab in RA patients on 
stable MTX who had inadequate responses to MTX, while 
SCRIPT [12] studied ocrelizumab in RA patients taking 
MTX or leflunomide who had inadequate responses to at 
least one TNF antagonist. Patients in the STAGE, FILM, and 
SCRIPT studies continued taking their stable doses of MTX 
or leflunomide and were assigned to receive ocrelizumab 
at 200 mg × 2, 500 mg × 2, or placebo × 2 at baseline and 
at week 24. FEATURE had a different study design, with 
Table 1  Characteristics of anti-CD20 mAbs





Rituximab Immunogenicity occurs due to chimeric nature NHL, CLL, RA, GPA, 
MPA
2nd Humanized Ocrelizumab Binds an overlapping epitope region as rituximab. Increased binding 
affinity. Enhanced ADCC and less CDC compared to rituximab [8, 32]
RRMS and PPMS
Veltuzumab Complementarity-determining regions are similar to rituximab. Greater 
binding avidity and effect on CDC than rituximab [8]
Orphan status designation 
for ITP and pemphigus
Obinutuzumab Binds to an epitope on CD20 that partially overlaps with that of rituxi-
mab. Greater ADCC than rituximab. Unlike rituximab, obinutuzumab 
does not stabilize CD20 in lipid rafts and thus has less CDC. More 
effective at direct B cell apoptosis [63]
With chlorambucil for 
previously untreated 
CLL
Fully human Ofatumumab Binds to an epitope distinct from that recognized by rituximab, ocreli-
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Table 2  Randomized controlled trials of next-generation anti-CD20 mAbs in autoimmune diseases
Drug Disease Criteria Study Format Status
Ocrelizumab RA Patients with inadequate response to MTX Phase I/II [15] NCT02720120 IV Terminated
RA Japanese patients with inadequate response to MTX Phase I/II [15] NCT00779220 IV Terminated 
early
RA Patients with inadequate response to etanercept and adalimumab Phase II [15] NCT00808210 IV Terminated
RA Patients on MTX ACTION, Phase I/II [13] 
NCT00077870
IV Completed
RA Patients on MTX STAGE, Phase III [9] 
NCT00406419
IV Terminated
RA Patients on MTX FILM, Phase III [10] 
NCT00485589
IV Terminated
RA Patients with inadequate response to TNF antagonist SCRIPT, Phase III [12] 
NCT00476996
IV Terminated
RA Patients with inadequate response to MTX FEATURE, Phase IIb [11] 
NCT00673920
IV Terminated








RRMS ≥ 2 relapses in the last 3 years with ≥ 1 in the past year 
and ≥ 6 T2 lesions per MRI, or 2 relapses in the last year
Phase II [24] NCT00676715 IV Completed
≥ 2 relapses in the last 2 years, 1 relapse in the last year, or 
MRI consistent with MS
OPERA I and II, Phase 
III [22] NCT01247324, 
NCT01412333
IV Approved
PPMS Patients meeting revised McDonald criteria and disease 
duration < 15 years if EDSS > 5.0, < 10 years if EDSS ≥ 5.0
ORATORIO, Phase III [23] 
NCT01194570
IV Approved
RRMS Patients meeting revised McDonald criteria, ≥ 1 release in 
last year, disease duration ≤ 3 years, EDSS ≤ 3.5
Phase III NCT03085810 IV Recruiting
RRMS 
PPMS
Patients from OPERA I, OPERA II, or ORATORIO;  
clinically stable
Phase III NCT01765361 IV Completed
RRMS Patients meeting revised McDonald criteria, EDSS ≤ 5.5, 
≥ 1 immunization against TT, DT, or DTaP
Phase IIIB NCT02545868 IV Ongoing
RRMS Patients meeting revised McDonald criteria, disease dura-
tion ≤ 12 years, suboptimal response to other DMT
Phase III NCT02637856 IV Recruiting
RRMS Patients meeting revised McDonald criteria, disease dura-
tion ≤ 12 years, suboptimal response to other DMT
Phase III NCT02637856 IV Recruiting
Ofatumumab RA Patients with inadequate response to DMARDs Phase I/II [18] NCT00291928 IV Completed
RA Biologically naïve patients who failed at least one DMARD OFA111752, Phase II extension 
[17] NCT00655824
IV Terminated
RA Biologically naïve patients who failed MTX OFA110635, Phase III [16] 
NCT00611455
IV Terminated
RA Biologically naïve patients who failed TNF antagonist OFA110634, Phase III [17] 
NCT00603525
IV Terminated
RA Patients who failed MTX Phase I/II [19] NCT00686868 SC Completed
RRMS ≥ 2 relapses in the last 2 years, or ≥ 1 relapse in the last 
1–2 years and ≥ 1 T1 GEL in the last year
Phase II [25] NCT00640328 IV Completed
≥ 1 relapse in the last year, ≥ 2 relapses in the last 2 years, 
or ≥ 1 relapse in the last 2 years with GEL in the last year
MIRROR, Phase II [26] 
NCT01457924
SC Completed
Patients with at least 1 relapse in the last year, 2 relapses in 
2 years, or GEL MRI in last year






Patients with moderate or severe disease who failed a 
steroid taper
Phase III NCT01920477, 
NCT02613910
SC Terminated
Obinutuzumab SLE Patients with active LN Phase II NCT02550652 IV Recruiting
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patients randomized to receive ocrelizumab at 200 mg × 2, 
500 mg × 1 (single infusion), or placebo × 2. At 24 weeks, 
dual infusion groups were re-randomized to either ocreli-
zumab dosing regimen. At 48 weeks, the open-label period 
began and patients received ocrelizumab at 400 mg × 1.
All phase III trials met their primary endpoints for all 
doses of ocrelizumab, with the exceptions of the FEATURE 
single infusion group and FILM, which was terminated 
prematurely. Compared to placebo, a greater percentage 
of ocrelizumab-treated patients in the FEATURE study 
achieved the American College of Rheumatology 20% cri-
teria for improvement (ACR20) at week 24. Similarly, the 
STAGE and SCRIPT studies showed a greater percentage of 
ocrelizumab-treated patients with ACR20 at weeks 24 and 
48, compared with placebo. However, SCRIPT also showed 
that joint progression on X-ray based on the modified Sharp/
van der Heijde score was only slowed in the higher dose 
500 mg ocrelizumab group. Finally, FILM found a reduced 
change from baseline in the modified Sharp/van der Heijde 
score at week 52, although its original primary endpoint was 
at 104 weeks.
SCRIPT and STAGE showed that the number of  CD19+ 
peripheral B cells was higher in the ocrelizumab 200 mg 
group compared to the 500 mg group, at weeks 24 and 48. 
This was consistent with results in ACTION, an earlier 
phase II study of ocrelizumab in RA patients on MTX [13]. 
These findings suggest that the higher ocrelizumab dose is 
more effective in prolonged peripheral B cell depletion. In 
FEATURE, greater B cell repletion was found in the single 
infusion group at week 24, suggesting that the double infu-
sion administration is more effective in prolonged B cell 
depletion.
In terms of immunogenicity, at pre-infusion baseline, 
0.6% of all patients were HAHA positive, which was 
expected given the assay used [14]. Across all four trials, 
a low proportion of patients developed HAHA positivity 
during the double-blind placebo-controlled periods. HAHA 
incidence was comparable between the ocrelizumab plus 
MTX and placebo plus MTX groups, ranging from 1.0 to 
4.7% in each treatment arm. In FEATURE, HAHA inci-
dence ranged from 0% in placebo-treated patients who 
then received ocrelizumab at 200  mg  ×  2 to 10.7% in 
placebo-treated patients who then received ocrelizumab 
at 400 mg × 1. There was no association between HAHA 
positivity and  CD19+ B cell counts or Disease Activity 
Score in 28 joints. Of the three patients who had a serious 
infusion-related reaction (IRR), none were HAHA positive. 
Meanwhile, of the patients who were HAHA positive, four 
had mild grade 1 or 2 IRRs.
An analysis of all the phase III trials SCRIPT, STAGE, 
FILM, and FEATURE concluded that ocrelizumab at doses 
of 500 mg plus MTX treatment groups were associated with 
a higher rate of serious infections compared to placebo plus 
MTX, whereas ocrelizumab 200 mg doses plus MTX did 
not show higher serious infection rates [9]. During the dou-
ble-blind placebo-controlled period, three deaths occurred 
in the ocrelizumab 500 mg dose group due to respiratory 
failure secondary to pneumonia, pneumonia complicated by 
sepsis, and acute myocardial infarction, while one patient 
in the placebo group died of mesenteric vasculitis. Serious 
adverse effects were more frequent in patients recruited in 
Asia, particularly Japan, who received ocrelizumab 500 mg 
doses plus MTX. This was true even after correcting for 
risk factors such as cardiac disease, use of oral corticos-
teroids at baseline, and history of diabetes. It is not clear 
why patients from Asia disproportionately accounted for the 
serious adverse events; however, Asian groups were made 
up of small numbers of patients and confidence intervals 
were wide and overlapped with other groups. Additionally, 
a separate phase I/II trial performed in Japan found increased 
infection and serious infection rates in ocrelizumab-treated 
groups and was terminated early [15]. Two other phase I 
and II trials were also terminated given poor benefit–risk 
profiles in RA treatment (NCT02720120, NCT00808210). 
After evaluating the efficacy and safety results from avail-
able trials, the sponsor ultimately decided that the benefit 
over current treatments, including rituximab, did not justify 
further development of ocrelizumab as a treatment for RA 
[12]. In May 2010, ocrelizumab development in RA was 
terminated [14].
Ofatumumab in RA
Between January 2008 and July 2013, three clinical trials 
were conducted to evaluate the long-term safety and efficacy 
of repeated treatment cycles of IV ofatumumab in differ-
ent populations of RA patients. OFA110635 was a study 
of IV ofatumumab in biologically naive RA patients who 
had failed MTX [16], while OFA110634 was a study of IV 
ofatumumab in biologically naive patients who had failed 
TNF antagonists [17]. These were both phase III trials with 
24-week randomized, double-blind, placebo-controlled peri-
ods followed by 120-week open-label retreatment periods, 
and then safety follow-up for up to 2 years. Patients across 
both trials received a course of two infusions of 700 mg 
ofatumumab or placebo given 2 weeks apart. Patients could 
be re-treated if clinically indicated, and remained on their 
stable doses of MTX. In OFA110635, a greater proportion 
of ofatumumab-treated patients, 50% vs. 27% with pla-
cebo at 24 weeks (p < 0.001), achieved ACR20 responses. 
OFA110634 had similar results at 24 weeks, with ACR20 
in 42% of patients with ofatumumab vs. 19% with placebo 
(p value was not published). OFA111752 was a phase II 
extension trial with a 130-week open-label period and 
safety follow-up [16]. The study followed RA patients who 
failed at least one disease-modifying antirheumatic drug 
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(DMARD) who were enrolled in a prior phase I/II dose-
ranging trial. They had originally received ofatumumab at 
300, 700 or 1000 mg doses or placebo [18]. In the extension 
phase, patients received individualized open-label ofatu-
mumab retreatment of 700 mg × 2 intravenous infusions 
given 2 weeks apart, ≥ 24 weeks after their first course and 
≥ 16 weeks after further courses. The primary endpoint of 
the phase II extension was time to treatment withdrawal. 
While preliminary results were promising, the trials were 
discontinued prematurely due to the sponsors deciding to 
shift ofatumumab development to a subcutaneous (SC) 
formulation.
These studies showed that IV ofatumumab was effec-
tive in decreasing disease activity, and inducing remission 
in RA patients who had inadequate responses to MTX, 
TNF antagonists, or other DMARDs [17]. Additionally, 
individualized retreatment with ofatumumab infusions at a 
dose of 700 mg × 2 was efficacious and safe in RA patients. 
Given premature termination, only limited data on anti-
drug antibodies are available. All 92 samples from patients 
tested in OFA111752 were negative for anti-drug antibod-
ies, and there were no major observed differences across 
trials involving RA patients who were biologically naive, 
DMARD refractory, or those who had prior exposure to TNF 
antagonists. Across trials, mild to moderate IRRs were com-
mon (48–79%), while serious IRRs were uncommon (< 1% 
to 5% of patients). Given frequent IRRs, demonstrated tech-
niques to reduce the IRRs were implemented, including 
increased infusion volume, increased infusion time, and pre-
medication with IV glucocorticoids. Two deaths occurred, 
one due to fulminant hepatitis B virus infection and the other 
due to interstitial lung disease.
As an alternative to the IV route and to eliminate the 
need for premedication with glucocorticoids, a SC formula-
tion was investigated with the rationale that SC ofatumumab 
could achieve a slower rate of absorption and B cell deple-
tion and potentially improve safety and tolerability. The 
sponsors began testing a SC formulation of ofatumumab in 
a 24-week phase I/II, single-blind trial with extended follow-
up for up to 2 years to evaluate its safety and tolerability in 
RA patients who failed MTX [19]. Patients received a single 
SC injection of ofatumumab at 0.3, 3, 30, 60, or 100 mg 
doses or placebo with oral antihistamine and acetaminophen 
premedication. Full target B cell depletion was achieved in 
patients who received a single dose of 30, 60, or 100 mg. 
Doses up to 60 mg were tolerated without glucocorticoid 
premedication. Injection-related systemic adverse events, 
including nausea, fever, dizziness, and headache, were 
mostly mild or moderate and more common in the ofatu-
mumab-treated group, 48% vs. 25% with placebo. Notably, 
adverse events occurred in all three patients receiving the 
100 mg dose of ofatumumab. Upper respiratory infection 
was a common adverse event, but no serious infections 
occurred. The doses used in this study are remarkably 
lower than those used in IV formulations, and still effective 
at depleting peripheral B cells. Doses between 30 to 60 mg 
appear to be well tolerated. The ability to use these lower 
doses could have major implications for the delivery, cost, 
and accessibility of anti-CD20 mAbs, but further studies will 
be needed to determine efficacy, optimal dosing schedule, 
and long-term safety in RA patients.
Veltuzumab in RA
A dosing study of SC veltuzumab was initiated in patients 
with RA, but the sponsor decided to terminate it and rede-
sign the protocol (NCT01390545).
Anti‑CD20 mAbs in multiple sclerosis
MS is a chronic demyelinating autoimmune disease of the 
central nervous system which affects approximately 2.5 mil-
lion people worldwide. After success in RA trials, rituxi-
mab was investigated as a treatment for RRMS and PPMS. 
Results of phase II trials were favorable in RRMS [20] and 
a subset of PPMS patients who were less than 51 years old 
and/or had gadolinium enhancing lesions (GEL) [21]. How-
ever, the sponsor decided to shift the focus to developing 
ocrelizumab.
Ocrelizumab in MS
Three recent landmark clinical trials of ocrelizumab in 
MS have been completed. OPERA I and II were identical 
96-week phase III, multicenter, randomized, double-blind, 
double-dummy, active-controlled, parallel-group trials 
investigating ocrelizumab vs. interferon β-1α (IFN β-1α) in 
RRMS [22]. Ocrelizumab IV infusions were administered at 
a dose of 600 mg every 24 weeks, while IFN β-1α SC injec-
tions were administered at 44 µg three times/week. The ocre-
lizumab group met its primary endpoint, with statistically 
significant reductions in annualized relapse rate at 96 weeks. 
In OPERA I, ocrelizumab-treated patients had a 46% lower 
relapse rate with 0.16 vs. 0.29 (p < 0.001), and similarly in 
OPERA II, there was a 47% lower rate with 0.16 vs. 0.29 
(p < 0.001). Ocrelizumab-treated patients also had a statisti-
cally significantly lower percentage of patients with disabil-
ity progression at 12 and 24 weeks, lower mean number of 
GEL on T1-weighted MRI, and better MS functional com-
posite scores. Immunogenicity was limited, with only 0.4% 
of ocrelizumab-treated patients across the two trials develop-
ing anti-drug antibodies. In contrast, neutralizing IFN β-1α 
antibodies were found in 21.3% of IFN β-1α-treated patients. 
Across the two trials, IRRs were more common in the ocreli-
zumab group at 34.3%, but only occurred in 9.7% of patients 
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in the IFN β-1α group. Serious infections were comparable, 
occurring in 1.3% of the ocrelizumab group vs. 2.9% in the 
IFN β-1α group, as were neoplasms which occurred in 0.5% 
vs. 0.2%, respectively. Overall, ocrelizumab was found to 
be superior to IFN β-1α in terms of efficacy with a similar 
safety profile, aside from common IRRs with ocrelizumab.
ORATORIO was a 120-week phase III, randomized, 
parallel-group, double-blind, placebo-controlled trial that 
studied ocrelizumab vs. placebo in PPMS [23]. Patients were 
assigned to receive IV ocrelizumab at 600 mg or IV pla-
cebo every 24 weeks. ORATORIO met its primary endpoint, 
with a statistically significant decrease in the percentage of 
patients with disability progression at 12 weeks at 32.9% 
with ocrelizumab vs. 39.3% with placebo (p = 0.03). Similar 
trends followed at 24 and 120 weeks. By week 120, fewer 
ocrelizumab-treated patients had declined performance on 
the timed 25-foot walk, total volume of brain lesions on 
T2-weighted MRI decreased, and there was a lower per-
centage of brain-volume loss. There was, however, no sig-
nificant difference in the change in the Physical Component 
Summary score of the 36-Item Short-Form Health Survey. 
Adverse events that were more common with ocrelizumab 
than placebo were IRRs, upper respiratory tract infections, 
and oral herpes infections. There was an imbalance of neo-
plasms, which occurred in 2.3% of ocrelizumab-treated 
patients vs. 0.8% with placebo, but there was no clinically 
significant difference in the rates of serious adverse events 
and serious infections. Although statistically significant 
improvements in clinical and MRI progression were dem-
onstrated in ORATORIO, the effects could be considered 
modest. Additionally, it is important to note that the ORA-
TORIO trial was not powered to demonstrate a difference in 
the subgroup analysis of efficacy between patients with and 
without GEL at baseline. Given that earlier trials of rituxi-
mab in PPMS suggested its efficacy was limited to a subset 
of patients with GEL [21], it is possible that ocrelizumab 
might benefit PPMS patients with an inflammatory-predom-
inant form of the disease more than the neurodegenerative 
form. Further studies are required to determine which subset 
of PPMS patients benefit most from ocrelizumab.
While ocrelizumab in RA was met with safety concerns 
regarding serious infections (“Ocrelizumab in RA”), this 
has not been the case with MS trials to date. However, 
safety concerns were raised during the open-label exten-
sion phases of ocrelizumab in MS trials when an imbalance 
of malignancies presented. In the ocrelizumab-treated MS 
patients across all four studies, including the phase II study 
in RRMS (NCT00676715) [24], incidence of a first neo-
plasm was 0.40 per 100 patient-years of exposure vs. 0.20 
out of 100 patient-years in the comparator groups (placebo 
and IFN β-1α) [23]. Ocrelizumab has recently been granted 
FDA approval for both RRMS and PPMS, and represents the 
first FDA-approved treatment for PPMS. Further studies to 
better characterize the utility of ocrelizumab are underway, 
including use in early-stage RRMS (NCT03085810), use 
in patients with RRMS and inadequate response to other 
disease-modifying therapies (DMTs) (NCT02637856), 
immune response to vaccines after a dose of ocrelizumab 
(NCT02545868), and effect on the neurodegenerative subset 
of RRMS and PPMS patients using subsamples from the 
ORATORIO and OPERA I and II trials (NCT01765361). 
Ocrelizumab currently carries a black box warning for hepa-
titis B reactivation, but continued monitoring will be neces-
sary to appropriately assess ocrelizumab’s long-term safety 
profile in MS.
Ofatumumab in MS
Ofatumumab has undergone two phase II trials in RRMS. 
One study was designed as a 48-week phase II, randomized, 
double-blind, placebo-controlled trial assessing safety and 
preliminary efficacy of IV ofatumumab. It compared ofatu-
mumab infusions at 100, 300, and 700 mg doses vs. placebo 
for weeks 0–24, at which point patients crossed over to the 
alternative study arm for weeks 24–48 [25]. MRI data sug-
gested efficacy at all doses studied, which were lower than 
the 1000 mg doses of rituximab used in off-label RRMS 
treatment, potentially due to ofatumumab’s increased 
potency over rituximab. IRRs were the most common 
adverse event and more common in the ofatumumab-treated 
group, occurring in 88.5% of patients with ofatumumab vs. 
8.3% with placebo. No cases of opportunistic infections or 
neoplasms were reported. No immunogenicity was detected 
in any of the ofatumumab-treated patients. Overall, IV ofatu-
mumab had a favorable safety profile and promising results.
Due to the high rate of IRRs with IV ofatumumab and 
the favorable safety profile demonstrated by a phase I/II 
trial for SC ofatumumab in RA patients [19], a study of 
SC ofatumumab in MS was conducted. The MIRROR trial 
was a 24-week phase II, randomized, double-blind, placebo-
controlled, parallel-group, dose-ranging study in RRMS in 
which ofatumumab was administered as SC injections [26]. 
Patients received 3, 30, or 60 mg SC doses every 12 weeks, 
60 mg SC every 4 weeks, or placebo. At week 12, patients 
on placebo received a single dose of 3 mg SC ofatumumab. 
Data from weeks 0–12 showed a statistically significant 
reduction in new T1 GEL of 65% (p < 0.001) compared 
to placebo. Injection-related reactions were the most com-
mon adverse event, occurring in 52% of ofatumumab-treated 
patients vs. 15% of placebo. Five serious adverse events 
were reported during treatment, but there were no cases of 
opportunistic infections.
The sponsor is currently recruiting for phase III trials, 
ASCLEPIOS I and II, of SC ofatumumab vs. oral teriflu-
nomide in relapsing MS [27]. SC injection is a new route 
of administration of anti-CD20 mAbs that surely has the 
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potential to compete with other injectable MS treatments, 
such as interferon beta’s, and carries an advantage over-
infused anti-CD20 mAbs.
Anti‑CD20 mAbs in systemic lupus 
erythematosus
SLE is a chronic inflammatory disease with prominent 
immunologic abnormalities including antinuclear antibodies 
that can impact virtually every organ. When SLE affects the 
kidneys, it is referred to as lupus nephritis (LN). Currently, 
in SLE immunotherapy, there is no anti-CD20 mAb dem-
onstrated to be effective in randomized controlled trials [5]. 
Rituximab has been effective in several open-label, uncon-
trolled studies, and a systematic review found improved 
outcomes with rituximab [28]. However, neither of the ran-
domized controlled trials, EXPLORER [29] and LUNAR 
[30], met primary endpoints. The EXPLORER trial, which 
studied rituximab in patients with active extra-renal SLE, 
involved excessive use of background immunosuppressants 
which may have been limiting. LUNAR studied rituximab 
in patients with active proliferative nephritis, and all patients 
received concomitant mycophenolate mofetil (MMF) and 
corticosteroids [30]. While the use of rituximab in SLE is 
controversial, it is nevertheless recommended in the Ameri-
can College of Rheumatology guidelines as a consideration 
for treatment of refractory cases of SLE [31].
Ocrelizumab in SLE
Two phase III studies of ocrelizumab in patients with SLE 
were started, and then terminated prematurely. BEGIN was 
a phase III study of ocrelizumab in patients with active, 
non-renal SLE, but was terminated early when its sponsor 
decided ocrelizumab was unlikely to benefit this popula-
tion (NCT00539838). Ocrelizumab was then investigated in 
BELONG, a multicenter, randomized, double-blind, placebo-
controlled, parallel-group phase II study, in SLE patients with 
progressive LN [32]. Patients were randomized to receive 
400 or 1000 mg ocrelizumab or placebo: at baseline, after 
2 weeks, then every 4 months thereafter. All patients addition-
ally received either cyclophosphamide or MMF. The cyclo-
phosphamide regimen was based on the EUROLUPUS trial, 
which studied low-dose cyclophosphamide in SLE treatment 
[33]. The BELONG study was designed to continue for at 
least 2 years, with the primary endpoint as renal response at 
48 weeks. The trial was terminated early due to an imbalance 
in rate of serious infections in the ocrelizumab group receiv-
ing MMF. 381 patients had been recruited, and 221 patients 
had passed the 32-week point and were assessed. The renal 
response rate was 63% and 51% in the combined ocrelizumab 
and placebo groups, respectively. Upon subgroup analysis, 
there was a greater treatment effect with adding ocrelizumab 
to the EUROLUPLUS cyclophosphamide regimen, with 
renal response of 65.7% compared to 42.9% with cyclophos-
phamide alone [33, 34]. The difference was much less pro-
nounced in the MMF regimen, with renal response rates of 
67.9% with ocrelizumab vs. 61.7% with MMF alone. This can 
be explained by the higher response rate with MMF in general 
and could shed light on why the LUNAR study of rituximab 
in SLE patients with proliferative lupus nephritis, which also 
used MMF, did not reveal clinical benefits.
Obinutuzumab in SLE
A phase II trial of the anti-CD20 mAb obinutuzumab plus 
MMF vs. placebo plus MMF in SLE patients with LN is 
actively recruiting patients (NCT02550652). Since the ben-
efits of rituximab or ocrelizumab have not been prominent 
with concurrent MMF treatment, it will be interesting to see 
if this will also be the case in this trial, which has similar 
treatment group regimens.
Veltuzumab in SLE
Veltuzumab was effective in a 2005 case study of a patient 
with severe, resistant SLE who failed conventional therapies 
and initially responded to rituximab. The patient then had 
clinical worsening of her disease and developed high levels 
of anti-rituximab antibodies. She received veltuzumab on 
a compassionate-use basis and responded well, with B cell 
depletion and remarkable clinical improvement [35]. It is 
unclear whether this is an isolated case or could be general-
ized to other patients with SLE refractory to rituximab, since 
veltuzumab has not been in development for SLE.
Anti‑CD20 mAbs in pemphigus
Pemphigus vulgaris and pemphigus foliaceus are chronic 
autoimmune blistering diseases that can result in significant 
morbidity and death. After initial reports of the benefits of 
rituximab in paraneoplastic pemphigus in patients treated 
with rituximab for B cell lymphoma, rituximab was found to 
be effective for pemphigus vulgaris and pemphigus foliaceus 
in retrospective studies, case series, and small uncontrolled 
trials [36–39]. The optimal dosing of rituximab for pemphi-
gus has not yet been determined. Rituximab is used in refrac-
tory cases of pemphigus and is usually prescribed concomi-
tantly with other systemic immunosuppressive therapies.
Veltuzumab in pemphigus
SC veltuzumab was used on a compassionate-use basis 
in a patient with refractory pemphigus vulgaris. Two SC 
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injections of 325 mg veltuzumab were given 2 weeks apart, 
which led to a complete remission for 2 years. At 2 years, 
the patient relapsed and received a second cycle of veltu-
zumab at the same dosing regimen. Remission was main-
tained 9 months later at the end of the follow-up period [40]. 
Veltuzumab was granted Orphan Status Designation by the 
FDA for pemphigus in 2015.
Ofatumumab in pemphigus
There was a phase III randomized clinical trial of SC ofatu-
mumab in pemphigus that recruited 35 patients, but it was 
terminated after ofatumumab was acquired by a different 
sponsor (NCT01920477).
Efficacy of anti‑CD20 mAbs
Next-generation anti-CD20 mAbs have been shown to be 
more potent than rituximab in vitro; however, this has not 
been confirmed in vivo. Thus far, there have been no head-
to-head trials of rituximab against the newer agents. How-
ever, a new phase III trial is now underway to directly com-
pare safety profile and tolerability in patients with RRMS on 
IV rituximab who switch to IV ocrelizumab vs. those who 
continue on rituximab (NCT02980042). More of these types 
of direct comparison studies will help determine whether 
there are true advantages, in terms of safety and efficacy, to 
the new anti-CD20 mAbs.
The development of antibodies to chimeric rituximab has 
raised concerns that immunogenicity of anti-CD20 mAbs 
could impact efficacy, tolerability and risk of IRRs. A safety 
analysis of RA patients treated with rituximab in combina-
tion with MTX in clinical trials showed that 11% of patients 
developed a positive titer for HACA’s at least once during 
treatment with rituximab [41]. However, the presence of 
HACA was not associated with IRRs or reduced efficacy 
upon retreatment. Additionally, in the HERMES trial, a 
phase II study of rituximab in RRMS, HACAs were detected 
in 24.6% of rituximab-treated patients at week 48, but there 
was no association between presence of HACA and effi-
cacy or adverse effects [7]. On the other hand, there is evi-
dence that suggests immunogenicity can affect the efficacy 
of rituximab in some patients. One case study described a 
young female patient with severe resistant SLE who initially 
responded to rituximab, but eventually, rituximab treatment 
became inadequate to control her disease, and high levels of 
anti-rituximab antibodies were found [35]. She then received 
veltuzumab on a compassionate-use basis and achieved dis-
ease remission. Therefore, it is possible that under dire situ-
ations when tolerance to an anti-CD20 mAb has developed, 
switching to another anti-CD20 mAb could potentially be 
useful.
Although there are no direct comparisons in immuno-
genicity between rituximab and the newer anti-CD20 mAbs, 
rates of immunogenicity appear lower with the newer anti-
CD20 mAbs. In the 48-week phase II study of ofatumumab 
in RRMS, none of the patients tested HAHA positive [25], 
while in the phase II study of ocrelizumab in RRMS the 
incidence of HAHA was similar between the ocrelizumab 
and placebo groups (2–3%) [24]. Furthermore, even in 
cases where HAHA develop there has not been a consistent 
association between immunogenicity and lack of efficacy 
or adverse effects. For example, in a phase I study of veltu-
zumab in idiopathic thrombocytopenic purpura (ITP), many 
patients developed immunogenicity to veltuzumab, but still 
showed clinical improvement [40].
Additionally, there is some evidence that the extent of 
autoimmune disease progression at time of first treatment 
can affect the efficacy of anti-CD20 mAbs. Studies suggest 
a possible enduring advantage of early control of pathogenic 
B cells in autoimmune disease progression, particularly in 
myasthenia gravis (MG) and ITP. A meta-analysis of uncon-
trolled observational studies of rituximab in patients with 
MG showed a trend toward an inverse correlation between 
the duration of disease and rate of response [42]. Similarly, 
in the phase I study of veltuzumab in ITP patients, there was 
a trend toward a longer median time to relapse in patients 
who had ITP for a year or less [43]. If similar results are 
found in the context of other diseases then it could alter 
future treatment management decisions, as physicians typi-
cally start newly diagnosed patients on the least potent and 
also safest treatment options first. If early treatment with 
anti-CD20 mAbs can curtail disease progression and demon-
strate a good safety profile, anti-CD20 mAbs may eventually 
become a first-line therapy in autoimmune diseases.
Safety profile of anti‑CD20 mAbs
If anti-CD20 mAbs are to become the new standard of care 
for a given autoimmune disease, they will need to offer an 
excellent safety profile. IRRs are the most common adverse 
events of anti-CD20 mAb infusions, including rituximab 
and newer anti-CD20 mAbs. IRRs are partially attributed 
to cytokine release after pronounced B cell depletion upon 
the first infusion [44]. IRRs occur primarily after the first 
infusion, are most often mild or moderate in severity, and 
rarely require discontinuation of treatment. Patients may 
experience local and systemic reactions including urticaria, 
angioedema, headache, nausea, fever, chills, rigors, and even 
bronchospasm and hypoxia in rare severe cases. Humanized 
and human anti-CD20 mAbs are theorized to cause reduced 
incidence and lower severity of IRRs compared to rituxi-
mab due to decreased immunogenicity. However, this has 
not been directly compared, and IRRs have continued to be 
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the most common adverse event with infusions of newer 
anti-CD20 mAbs.
SC formulations of anti-CD20 mAbs appear to be the next 
step in development, which could reduce IRRs, eliminate 
the need for premedication with glucocorticoids, and offer 
a potentially more convenient administration method. A SC 
formulation of rituximab has already been developed and 
approved in Europe in 2014 for use in patients with follicular 
lymphoma and NHL, and in 2016 for CLL. Ofatumumab 
is also being developed as a SC formulation for use in RA 
and RRMS, and a SC formulation of veltuzumab was in 
development for RA patients with plans to start a new trial 
after the protocol is redesigned [19, 26]. SC rituximab is 
administered over 5 min, and the patient needs to be moni-
tored for IRRs for at least 15 min after the injection. This 
is significantly less time compared with IV rituximab, with 
which patients need to be monitored throughout the infusion 
process lasting up to 6 h [45]. The SC route is preferred by 
93% of CLL patients and 95% of nurses, according to part 
one of the phase 1b SAWYER study investigating SC ver-
sus IV rituximab in patients with previously untreated CLL 
[46]. Adverse events are more frequent with the SC route 
compared with IV, but the most common adverse events are 
low-grade, local injection-site reactions including erythema 
and pruritus, which typically resolve within 1 to 2 days [45]. 
In November 2016, the FDA accepted the drug maker’s bio-
logics license application for a SC formulation of rituximab 
for several hematologic malignancy indications for use in 
the US.
The long-term consequences of B cell depletion are not 
known, but agents that interfere with the immune system 
raise concerns for infection and malignancy. Progressive 
multifocal leukoencephalopathy (PML) is a serious oppor-
tunistic infection that is of great concern with anti-CD20 
mAb use. It is a rare and often debilitating and fatal demy-
elinating disease of the central nervous system caused by 
JC virus infection of oligodendrocytes, and is typically only 
seen in patients with severely compromised immune sys-
tems. The broader use of immunosuppressive and biologic 
agents, including agents used in autoimmune disease treat-
ment, has presented the issue of iatrogenic PML [47, 48]. 
Cases of PML have been reported with rituximab use in 
patients with lymphoma, RA, SLE, GPA, and MG [49, 50]. 
Rituximab does carry black box warnings for hepatitis B 
reactivation and PML. However, there are differences in the 
incidences of PML in different subsets of patients using anti-
CD20 mAb treatment. The incidence of PML in rituximab-
treated RA patients is 1:30,000 [51]. Notably, PML cases 
in this subgroup occurred in patients who were previously 
or concurrently treated with additional immunosuppressive 
therapy, such as MTX. Immunosuppressed SLE patients 
have been found to be at a higher risk of developing PML 
than patients with other rheumatic disorders, with rates of 
PML in SLE patients at 4 per 100,000 admissions compared 
to 0.4 for RA patients and 2 for other connective tissue dis-
orders [52]. Several of the reported cases of PML in SLE 
patients have been attributed to rituximab [53]. In contrast, 
no cases of PML have been reported in MS patients, includ-
ing those with RRMS, SPMS, and PPMS, who have received 
rituximab in clinical trials, or with off-label use [7, 21, 54]. 
Since immunosuppression increases the risk of PML, the 
common use of additional immunosuppressants in RA and 
SLE, but not MS, could help explain this disparity in risk. 
Furthermore, anti-CD20 mAbs actually carry a lower risk 
for PML than some other MS treatments. For example, the 
incidence of PML using natalizumab treatment in MS and 
Crohn’s disease ranges from 1:100 to 1:1000 [51]. At this 
point, it is expected that the newer anti-CD20 mAbs will 
carry similar PML risk profiles as rituximab.
Ofatumumab was FDA approved for use in CLL in 2014, 
and carries black box warnings for reactivation of hepati-
tis B and PML. A PML-related death has occurred in an 
ofatumumab-treated patient with history of CLL and other 
comorbid malignancies [55]. Obinutuzumab was FDA 
approved in 2013 for CLL and also carries black box warn-
ings for hepatitis B reactivation and PML [56]. Veltuzumab 
is being developed for hematologic malignancies and has 
orphan status approval for ITP. No PML cases have been 
reported, but it is too early to make an assessment.
While the infection and PML risk is higher for anti-CD20 
mAb-treated patients with RA and SLE, the risk of develop-
ing malignancies appears to be higher for MS patients. An 
analysis of the phase II and III randomized clinical trials of 
ocrelizumab in RRMS and PPMS revealed an imbalance 
of malignancies in the ocrelizumab-treated groups [22, 23]. 
Meanwhile, an analysis of rituximab trials in RA patients 
found no increased risk of malignancy compared to other RA 
patients or the general US population [41]. Malignancy is a 
concern for patients with autoimmune diseases who would 
likely need repeated treatments over their chronic disease 
course. Now that ocrelizumab has been FDA approved for 
RRMS and PPMS, continued monitoring will be necessary 
to determine whether the risk of malignancy will warrant 
future warnings or limitations of use.
Prospective cost of anti‑CD20 mAbs
The effect on price competition of introducing new anti-
CD20 mAbs into the market, particularly those using SC 
administration at lower doses and biosimilars, is an open 
question. Historically, in the context of MS, the introduction 
of new disease-modifying agents has paradoxically raised 
prices of older drugs. Rituximab’s patent expired in Europe 
in February 2013 and more recently in the US in September 
2016. Meanwhile, a biosimilar of rituximab, Acellbia, has 
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already undergone phase III trials and was approved by the 
Ministry of Health of the Russian Federation in May 2014 
[57]. The FDA has approved four biosimilars (Zarxio, Inflec-
tra, Erelzi, and Amjevita) since 2015, and biosimilars of 
rituximab are in the pipeline [58]. Rituximab’s patent expira-
tion also parallels the pharmaceutical industry’s enthusiasm 
in recent years to develop the newer generation anti-CD20 
mAbs. In 2015, rituximab costs about $30,000 annually for 
the treatment of RA using the dosing schedule of two infu-
sions of 1000-mg doses totally given 2 weeks apart every 
6 months [59]. Off-label use for MS has used a similar dos-
ing schedule, so a similar price would be expected. This is 
considerably less than other disease-modifying MS drugs 
which are currently estimated to cost approximately $70,000 
to $80,000 or more annually [60]. This includes the first-gen-
eration treatments that were approved two decades ago: IFN 
β-1β, IFN β-1α, and glatiramer acetate, which have actually 
seen the most dramatic annual price increases, ranging from 
21.0% to 35.7% [61]. Notably, the drug maker of the newly 
approved ocrelizumab has set the annual cost of twice-a-
year infusions to the price of $65,000 [62]. Although the 
stated price is within the range or less than other current MS 
drugs on the market, it is still significantly more expensive 
than rituximab. If biosimilars of rituximab become FDA 
approved in the future, this may drive price competition 
and lower the cost of rituximab. Even so, it is unclear if 
rituximab or its biosimilars would be a viable option for MS 
patients since the FDA has now approved ocrelizumab for 
RRMS and PPMS. Ofatumumab has not yet been approved 
for treatment in autoimmune diseases, but with ongoing tri-
als of SC ofatumumab in MS and RA, it will likely become 
a major player if approved. The SC administration is likely to 
be a huge selling point for both physicians and patients, so it 
will be interesting to see if that is reflected in a higher cost.
Conclusion
Anti-CD20 mAbs have demonstrated that B cells are 
important players in autoimmune diseases beyond their 
role in the generation of autoantibodies. A better under-
standing of how B cells participate in the development of a 
particular autoimmune condition will eventually allow for 
the development of more targeted B cell-mediated thera-
pies. In the meantime, the latest generation of anti-CD20 
mAbs is demonstrating effectiveness for some autoimmune 
diseases such as RA and RRMS, in which the first genera-
tion was also beneficial, but appears to offer a better safety 
profile in terms of immunogenicity. Furthermore, the lat-
est formulations of ofatumumab offer the more convenient 
and better tolerated method of SC administration, while 
ocrelizumab offers the first FDA-approved treatment for 
PPMS. Ultimately, factors including efficacy, safety, tol-
erability, administration method, accessibility, cost, and 
patient preference will need to be considered on an indi-
vidual basis to determine the best approach to the use of 
anti-CD20 mAbs in autoimmune disease treatment.
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